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Received: 11th Jan 2017  Liposomes are vesicles comprising of spherical phospholipids making them useful for topical 
applications of drugs. Liposome research has been expanded considerably and nowadays, it is 
possible to construct a wide range of liposomes varying in size, phospholipids composition and 
surface characteristics. In dermatological diseases, the topical application of liposomes has 
proven to be of high therapeutic value. Liposomes can be used as carriers for hydrophilic as well 
as lipophilic therapeutic agents because of their amphipathic character. They may improve 
stabilization of instable drugs by encapsulating them. They have the potential to target drugs 
into the pilosebaceous structures and hence have an advantage for treatment of hair follicle-
associated disorders. Liposomal encapsulated drugs are found useful in the treatment of acne, 
atopic dermatitis, psoriasis, vitiligo, superficial vein thrombosis and hair removal etc 
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INTRODUCTION 
It is the skin which is directly accessible for topical application 
of drugs. Optimum topical delivery of drugs into the skin 
requires penetration of the vehicle through the stratum 
corneum, liberation of the drug from the vehicle, absorption of 
the drug through the different layers of the skin. Safety aspects 
of topical drug delivery include the reduction of the risk of 
local and systemic side-effects by using appropriate drug 
concentrations, optimal vehicles and valid treatment [1]. 
Liposomes were described in 1965 by Banghamet al., while 
studying the spontaneous aggregation of phospholipids into 
vesicles [2]. These vesicles were called liposomes. These were 
initially used as a model for membrane system studies [3]. 
Since 1970, liposomes have received considerable attention as 
a system for delivering drugs to the target tissue [3]. In spite of 
promising prospects, the systemic application of liposomal 
drugs has been limited but the topical application of liposomal 
preparations has attracted increasing attention in dermatology 
[4]. Liposomes are microscopic vesicles formed from 
phospholipids as biological membranes. A large group of 
biological membrane lipids that spontaneously form bi-layers 
in water are the phospholipids. The ability of phospholipids to 
form a bi-layer structure is because of their amphipathic 
character resulting from the presence of a polar or hydrophilic 
(water-attracting) head-group region and a non-polar, lipophilic 
(water-repellent) tail. Therefore, liposomes contain a lipophilic 
compartment within the bi-layer membranes and hydrophilic 
compartments between the membranes. Under the right 
conditions, water-soluble substances can be stored into the 
water phase and lipophilic substances into the lipid phase [5]. 
Liposomes may be small, unilamellar vesicles (SUVs 25–
50 nm in diameter), large, unilamellar vesicles (LUVs 50–
500 nm in diameter) or large multilamellar vesicles (LMVs 
500–10 000 nm in diameter). SUVs are less suitable for drug 
delivery because they lack stability and their volume is too 
small for entrapping drugs. The penetration of liposomes 
through the stratum corneum decreases with increasing 
diameters. Therefore, the preferred structures for drug delivery 
are LUVs that are 50–500 nm in diameter. LUVs made from 
lipid mixtures containing unsaturated phosphatidyl 
ethanolamine can fuse and mix with the skin lipids to loosen 
their structure providing a penetration enhancing effect [6] 
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The skin acts as a two-way barrier, controlling the inward and 
outward passage of water and electrolytes. This barrier is 
situated in the stratum corneum and consists of the cornified 
material of the terminal differentiated keratinocytes, proteins 
and intercellular lipids. The main function of the cornified 
envelope is to form the outermost barrier layer of the skin, 
which prevents water loss and keeps out allergens and 
infectious agents [7]. Thus, the stratum corneum contains 
hydrophilic and lipophilic compartments, which act as a buffer 
to retard both water loss and absorption of water [8]. These 
lipid-rich structures might also influence the desquamation 
process in the stratum corneum [9]  
 
MECHANISM OF PENETRATION OF LIPOSOMES 
There are 3 mechanisms of penetration of liposomes into skin: 
 Via lateral diffusion of liposomes in the stratum corneum. 
The molecular structure of liposomes is similar to that of 
endogenous skin lipids. Lipid exchange occurs via 
molecular diffusion from one membrane to the other. The 
rate of phospholipid exchange depends upon the relative 
sizes of the hydrophobic portions of the molecule[10] 
 Via a trans-epidermal osmotic gradient and hydration 
force through which liposomes are sucked into the 
epidermis. An effective penetration of liposomes into the 
skin requires a dry skin surface[11] 
 Via the pilosebaceous units[12] 
The similarity of lipid composition of liposomes and 
membranes enables the liposomes to penetrate into the 
epidermal barrier to a greater extent as compared with other 
application forms [13]. This may result in an increase of drug 
absorption into the epidermis and decrease of drug clearance 
from the epidermis, promoting longer sustained release of 
drugs in the epidermis and lower absorption of drugs into the 
blood. Liposomes fuse with the outer cell membrane and 
deliver their contents to the cytoplasm via endocytosis [14] 
(Fig 1). Liposome research has expanded considerably over the 
last 30 years, and nowadays, it is possible to construct a wide 
range of liposomes varying in size, phospholipids composition 
and surface characteristics to suit the specific application for 
which they are intended.[16] .Liposomal formulations should 
have high entrapment efficiencies, narrow size distributions, 
long-term stabilities and ideal release properties. There are 
numerous lab-scale and a few large-scale techniques for 
liposome preparation giving rise to vesicles of different sizes 
and consisting of one or more bi-layers. Conventional and 
novel preparation techniques have been introduced, each with 
its own advantages and possible limitations.  
 
Figure 1 Liposomes fuse with the outer cell membrane and 
deliver their contents to cytoplasm of cells via endocytosis [15] 
 
ADVANTAGES OF LIPOSOMAL PREPARATIONS IN 
DERMATOLOGY 
1) The similarity of lipid composition of liposomes and 
membranes in the epidermis enables the liposomes to penetrate 
into the epidermal barrier to a higher extent as compared with 
other application forms and so do the compounds encapsulated 
into the liposomes. This may result in an increased drug 
absorption into the epidermis and a decreased clearance of drug 
from the epidermis resulting in a much longer sustained drug 
release and reduction of drug absorption into the blood. This is 
why liposomes may act as drug transporters as well as drug 
targeters. This may lead to increased effectiveness, reduction in 
side effects and a higher compliance of patients to treatment [3] 
2) Liposomes have also the potential to target drugs into the 
pilosebaceous structures and hence they can be employed for 
treatment of hair follicle- and sebaceous gland-associated 
disorders [12] 
3) Liposomes may serve as penetration enhancers facilitating 
the transport of compounds through the epidermis. The use of 
conventional penetration enhancers (e.g. dimethyl sulphoxide 
or propylene glycol) leads on the one hand, to an improved 
transport rate through the epidermal barrier but, on the other 
hand, to more unwanted side-effects because of an increased 
systemic drug level [17] 
4) In addition, irritant- and allergic reactions to penetration 
enhancers have been reported leading to the conclusion that 
addition of penetration enhancers does not always mean an 
advantage in topical drug administration [18] 
5) Side effects from liposomes are not to be expected because 
liposomes are similar to epidermal lipids, biodegradable and 
non-toxic [18] 
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6) Liposomes can be used as carriers for hydrophilic as well as 
lipophilic drugs because of their amphipathic character. 
Compounds like methotrexate and cyclosporin which cannot 
penetrate the epidermis may be usable for topical application 
when encapsulated in penetrating liposomes [19] 
7) Liposomes may also improve stabilization of instable drugs 
by encapsulating them [20] 
8) ‘Empty’ liposomes (without encapsulated drugs) hydrate the 
skin simply by contributing lipids to the stratum corneum. 
Additionally, the water content of liposomes promotes further 
hydration of the skin. In contrast with the ‘wet-wrap’ method, 
application of liposomal spray is a fast, easy procedure without 
any need of training. Liposomes help to reduce skin irritation to 
drugs (e.g. tretinoin) by hydration of the epidermis [20, 21] 
 
INDICATIONS FOR LIPOSOMES IN 
DERMATOLOGICAL DISEASES ACNE 
Acne is one of the most common disorders of the skin and has 
a considerable impact on the quality of life of adolescents. 
Standard treatment today consists of peeling the skin, 
eliminating the acnes and reducing inflammation by using 
topical benzoyl peroxide (BPO), tretinoin, adapalene and 
antibiotics. If this approach is not efficacious, systemic 
antibiotics and antiandrogens are the next step. However, the 
efficacy of antibiotic treatment is progressively reduced by 
increasing resistance of bacteria to antibiotics, and side-effects 
may also limit their use. In case of failure of treatment the final 
remedy is oral isotretinoin, which is very effective, even in 
recalcitrant acne, but its use is limited by moderate to serious 
side-effects. It was found that the efficacy and safety profiles of 
certain antiacne drugs may be improved by encapsulating them 
into liposomes [22] 
 
Figure 2: Acne on face [23] 
Liposome-encapsulated 1% clindamycin-solution was found to 
be superoior than 1% clindamycin-solution in the treatment of 
acne and no side-effects were reported [24]. Similarly, the   
efficacy and the local tolerability of liposomal tretinoin 0.01% 
was compared with  commercial gel preparation with either 
0.025% or 0.05% in 20 patients. The efficacy of liposomal 
tretinoin appeared to be equipotent to the reference gels, but 
liposomal tretinoin was superior with respect to skin 
irritancy.[25]. A comparative double-blind study in 30 patients 
demonstrated a 1.5-fold enhancement of drug efficacy and a 
marked decrease in all side-effects associated with tretinoin 
therapy for liposomal tretinoin gel compared with conventional 
tretinoin gels after 3 months of treatment [26]. BPO is an 
effective topical agent in the treatment of acne and acts by 
inhibition of the propionibacterium acnes in the pilosebaceous 
units. A comparative double-blind study of liposomal BPO vs. 
conventional BPO in 30 patients demonstrated a significant 
improvement in the therapeutic response (about 2-fold) after 
3 months of treatment with liposomal BPO as compared with a 
conventional BPO gel, with marked reduction in adverse 
symptoms and bleaching of clothing [27]. In another study, a 
significantly higher antibacterial effect of a BPO liposome 
formula was observed as compared with commercial BPO 
formulations [28] 
 
 ATOPIC DERMATITIS 
 
Figure 3: Atopic dermatitis of a child [29] 
In atopic dermatitis patients disturbance of the outermost 
barrier layer of the skin is observed due to mutation in the 
filaggrin  gene .[30] . This affects water permeability, leading 
to increased trans-epidermal water loss [31].Increased lamellar 
body secretion was demonstrated with coincidental clinical 
improvement after wet-wrap dressing treatment of atopic 
eczema [32]. Similar effects on the restoration of the skin 
barrier were described after application of liposomes on the 
skin. Due to the similarity between the structure of the 
liposomes and the lipid layers of the stratum corneum, the 
liposomes bind to the keratin layer of the stratum corneum and 
form a thin occlusive film, which reduces trans-epidermal 
water loss giving the patient immediate relief from the 
Kamra et. al
 
 Liposomes in dermatological diseases 
 
 
Journal of Applied Pharmaceutical Research  April  – June 2017  Volume 5 Issue 2  4 
discomfort associated with dry skin[.33]. Additionally, the 
water content of liposomes promotes further hydration of the 
skin. The wet-wrap treatment is very time-consuming, needs 
training and is not well tolerated by every patient. Application 
of liposomal spray is a fast, easy to use and requires no 
training. Moreover, a double-blind study showed that the 
patient's acceptance for liposomes containing preparations was 
significantly higher than that for commercially available 
moisturizing preparations [34]. Topically applied corticosteroid 
therapy is the first choice of treatment for atopic dermatitis and 
irritant and allergic contact dermatitis in addition to restoration 
of the damaged skin barrier and recognizing and elimination of 
a causative agent. Higher and sustained concentrations of a 
liposomal corticosteroid in the skin promise higher efficacy, 
less side-effects from absorption of corticosteroids into the 
blood and lower frequency of application.[35]. 
 
PSORIASIS 
Psoriasis is a long-lasting autoimmune which is characterized 
by patches of abnormal skin. These skin patches are typically 
red, itchy, and scaly. They may vary in severity from small and 
localized to complete body coverage. Injury to the skin can 
trigger psoriatic skin changes at that spot.  
 
Figure 4: Psoriasis on the back [36] 
Recent breakthroughs in the treatment of psoriasis have led to 
improved understanding of the pathogenesis of this disease[37]. 
Although major advances in the development and the use of 
targeted biologicals for controlling psoriasis have been made, 
the need to develop safe, cost-effective and disease-effective 
cures remains [38]. Vitamin D3 analogues such as calcipotriol, 
calcitriol and tacalcitol can be used in psoriasis. Calcitriol was 
tested at concentrations of 5, 15 and 20 µg/g in liposomes and 
in petrolatum in a mouse tail test. It was considered that by 
using a liposomal preparation, the vitamin D3 concentration can 
be reduced as compared with commercial preparations without 
affecting therapeutic effect and also reducing local side-effects 
such as skin irritation and systemic side effects [39]. Similarly 
Dithranol which is used in plaque type psoriasis, is considered 
inconvenient and troublesome because of  side-effects such as 
skin irritation, burning sensation, staining and necrotizing 
effect on normal as well as the diseased skin. The entrapment 
of dithranol in liposomal vesicles promotes its bioavailability in 
the epidermis, which makes it possible to reduce the dose and 
in turn, the dose-dependent side effects [40].  In a double-blind 
study, the superiority of 0.5% dithranol encapsulated in a 
liposomal gel as compared with a conventional cream 
containing 1.15% dithranol, 1.15% salicylic acid and 5.3% coal 
tar was reported [41]. Cyclosporine A (CyA), a potent 
immunosuppressive drug can be used in psoriasis .But systemic 
administration causes serious side-effects, such as  
nephrotoxicity. Topical administration is hindered because of 
its physicochemical properties and the barrier property of 
statumcorneum. .However  liposomal vesicles containing 10% 
and 20% ethanol showed statistically enhanced deposition of 
CyA into the stratum corneum causing topical delivery of CyA 
using liposomes  for the treatment of  skin diseases like 
psoriasis [42]. Similarly systemic methotrexate can be used for 
controlling recalcitrant psoriasis,but may cause hepatotoxic 
effects. topical application of methotrexate is limited being  the 
drug is hydro-soluble  limited for passive diffusion. However, 
in a liposomal preparation, 50% of the administered dose was 
found in the skin indicating that liposomes may be valuable in 
the topical application of methotrexate in the treatment of 
psoriasis[43].It was confirmed that psoriasis can be treated by 
topical application of liposomal-entrapped methotrexate-
paraffin wax in a small clinical trial. After 2 weeks of 
treatment, all plaques treated with liposomal methotrexate 
showed total clearance whereas those receiving free 
methotrexate didn’t improve [43].  
 
VITILIGO 
Vitiligo is an acquired de-pigmentation disorder affecting about 
1% of the population. It may have an important negative 
impact on the quality of life, particularly of those with 
pigmented skin.  The inactive melanocytes in the outer root 
sheath of the hair follicles are not affected. Phosphatidylcholine 
liposomes are able to target molecules like khellin into the hair 
follicles After khellin is activated by ultraviolet A (UVA) and 
UVB, the inactive melanocytes proliferate and mature to an 
active state as they migrate into the epidermis[44]. The results 
of systemic khellin in combination with UVA are comparable 
with the rates reported from psoralenphotochemotherapy 
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(PUVA)[45] The major advantage of khellin is that it does not 
induce photo-toxic skin erythema and does not induce 
detectable DNA mutations in contrast to PUVA, but side-
effects such as liver dysfunction have been reported. Topical 
photochemotherapy of vitiligo with khellin has also been 
reported to be efficacious.[46] The efficacy and the safety of 
topical treatment with 0.005% khellin encapsulated in l-
phenylalanine stabilized phosphatidylcholine liposomes in 
combination with UVA/UVB light (KPLUV) therapy was 
demonstrated in 74 patients with vitiligo in a retrospective open 
trial [47] 
 
SKIN CANCER 
Skin cancer is the most common cancer in white people[48]. 
Basal cell carcinoma and squamous cell carcinoma are the most 
frequently occurring skin cancers[49].  Exposure to solar UV 
radiation is the main  factor leading to the formation of skin 
cancers.[50]. Wavelengths especially in the UVB (280–
320 nm) range damage DNA in the cells of human skin 
[51].The bacteriophage T4 produces a DNA repair enzyme (T4 
endonuclease V), which is able to substitute the UV-damaged 
enzyme complex in humans to initiate excision repair[52]. It 
has been shown thatT4N5 containing liposomes protect the 
skin from UV-induced carcinogenesis by promoting the DNA 
repair and by inhibiting immunosuppression [53]. 
Photodynamic therapy (PDT) is widely used to treat actinic 
keratoses and superficial basal cell carcinoma. While changing 
the 5-ALA vehicle from a moisturizing cream to liposome 
encapsulation, the 5-ALA concentration can be lowered. 
Moreovera higher skin retention and a lower skin permeation 
of 5-ALA was demonstrated as compared with 5-ALA in 
aqueous solution[54]. The results of these studies indicated that 
5-ALA in liposomes may be adequate for the 5-ALA PDT 
treatment of skin cancer because the liposomes deliver 5-ALA 
to the target skin layers (viable epidermis and dermis) [54]. 
Liposomes provide the opportunity for a more precise targeting 
of drugs into diseased cells and may contribute to optimize the 
quality of fluorescence diagnosis. This property of liposomes 
as a targeting method is not available in other topical 
applications [55] 
 
THROMBOPHLEBITIS 
Thrombophlebitis is vein inflammation related to thrombus 
(blood clot). Its symptoms include pain, skin redness, oedema 
and inflammation.  
 
Figure  5: Thrombophlebitis on leg [56] 
Superficial vein thrombosis is generally considered to be 
relatively harmless. However, deep venous thrombosis and 
pulmonary embolism following superficial vein thrombosis 
have been reported[57] Therefore, the importance of treatment 
with low molecular weight heparin (LMWH) in addition to 
compression therapy has increased, mainly because of the 
antithrombotic actions of heparin[58]. Topical liposomal 
heparin spray-gel appeared to be equally efficacious in 
reduction of pain, erythema and thrombus size as compared 
with subcutaneous injections of LMWH.[58]. Subcutaneous 
injections and applications of topical LMWH in ointment, 
cream & gels are painful (rubbing into skin at thrombophlebitis 
site) in contrast with liposomal heparin spray gel [59] 
 
HAIR REMOVAL 
Unwanted facial and body hair can represent a severe cosmetic 
disturbance with social and psychological implications often 
strong enough to motivate patients, especially women, to seek 
dermatologic treatment. The goal of laser hair removal is to 
damage stem cells in the bulge of the follicle or to replace the 
hair follicle at the level of the dermis with connective tissue 
through thermal injury. The primary mechanism of laser hair 
removal is selective photothermolysis whereby follicular 
melanin is the target chromophore for destruction by light 
energy. Laser hair removal of white, blond and grey hair is 
often unsuccessful due to the lack of melanin in the hair 
follicle.  Melanin-encapsulated liposomes have demonstrated to 
deliver melanin selectively to the hair follicle and the hair 
shaft. (Hoffman 1998) Melanin-encapsulated liposomes 
(Lipoxome®) are used for staining hair follicles of people with 
blond, white or grey hair [60]. Pretreatment with Lipoxome® 
spray improved also the results of long pulsed Nd:Yag laser 
treatment for pigmented underarm hair. At 6 months after three 
laser treatment sessions, the percentage of hair reduction was 
73% with the combined therapy and 43% with laser treatment 
alone [61] 
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TOPICAL ANAESTHESIA FOR SUPERFICIAL 
SURGERY 
It was found that there is no need for occlusion after 
application of tetracaine 5% or lidocaine 4% in liposomal 
cream. Adequate anaesthesia is obtained after 30 min, 
vasoconstriction does not occur and there is no association with 
methemoglobinemia [62] 
 
SKIN REJUVENATION 
It was observed that Photo dynamic therapy ( PDT )with 5 
ALA  ( 20%) rejuvenated the  skin in the irradiated area, which 
resulted reduction of wrinkles, scars and large skin 
pores.[63,64]but the  side-effects were very high.such as pain, 
oedema, erythema etc..Comparable clinical results were 
obtained by 1 to 2-h application of 5-ALA 0.5% liposomal 
solution with less side effects [65]. Tretinoin can be used to 
treat acne, for skin rejuvenation, to treat sun-damaged skin and 
to prevent epithelial (pre)malignancies because of its ability to 
regulate sebum production, collagen synthesis and epithelial 
cell growth and differentiation.[66,67].It has been 
demonstrated that the effect is  promoted by incorporation of 
tretinoin in liposomes  as compared with tretinoin in a 
conventional cream [68] 
 
CONCLUSION 
Topical applications of liposomes is rational, based on clinical 
data  and pharmacological point of view because of their 
advantages over other application forms.The similarity of 
lipidcomposition of liposomes and membranes in the epidermis 
enables the liposomes to penetrate into the epidermal  barrier to 
a higher extent which may result  in an increased drug 
absorption into the epidermis leading to increased effectiveness 
and reduction of side effects.  
 
Moreover liposomes have the potential to target drugs into the 
pilosebaceous structures so can be used for treatment of hair 
follicle and sebaceous gland disorders. Liposomes may also 
serve as penetration enhancers facilitating the transport of 
compounds through epidermis. This made liposomes effective 
in various dermatological diseases such as atopic dermatitis, 
psoriasis, acne and vitiligo etc. 
 
REFERENCES  
[1] Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. 
Dermatology, New York: Springer-Verlag, 2000.  
[2] Bangham AD, Standish MM, Watkins JC. Diffusion of 
univalent ions across the lamellae of swollen 
phospholipids. J Mol Biol. 1965; 13: 238–252 
[3] Schmid MH, Korting HC. Therapeutic progress with 
topical liposome drugs for skin disease. Adv Drug Del 
Rev. 1996; 18: 335–342. 
[4]  Hope MJ, Kitson CN. Liposomes: a perspective for 
dermatologists. Dermatol Clin. 1993; 11: 143–154.  
[5] Egbaria K, Weiner N. Liposomes as a drug delivery 
system. Adv Drug Del Rev. 1990; 5: 287–300. 
[6] Maghraby GM, Barry BW, Williams AC. Liposomes and 
skin: from drug delivery to model membranes. Eur J 
Pharm Sci. 2008; 34: 203 
[7] Grath JA, Uitto J. The filaggrin story. novel insights into 
skin barrier function and disease. Trends Mol Med .2008; 
14: 20–27. 
[8] Imokawa G, Akasaki S, Minematsu Y, Kawai M. 
Importance of intercellular lipids in water-retention 
properties of the stratum corneum: induction and recovery 
study of surfactant dry skin. Arch Dermatol Res .1989; 
281: 45–51.  
[9] Fartach M. Epidermal barrier in disorders of the skin. Micr 
Res Techn.1997; 38: 361–371.  
[10] Cevc G. Transfersomes, liposomes and other lipid 
suspensions on the skin. permeation enhancement, vesicle 
penetration, and transdermal drug delivery. Crit Rev Ther 
Drug Carrier Syst.1996; 13: 257–388. 
[11] Cevc G, Blume G. Lipid vesicles penetrate into intact skin 
owing to the transepidermal osmotic gradients and 
hydration force. BiochimBiophysActa. 1992; 1104: 226–
232.  
[12] Lieb L, Ramachandran C, Egbaria K, Weiner N. Topical 
delivery enhancement with multilamellar liposomes into 
pilosebaceous units. In vitro evaluation using fluorescent 
techniques with hamster ear model. J Invest Dermat.1992; 
99: 108–113.  
[13] Plessis J, Egbaria K, Weiner N. Influence of formulation 
factors on the deposition of liposomal components into the 
different strata of the skin. J SocCosmet Chem. 1992; 43: 
93–100.  
[14] Ostro M. Liposomes. Sci Am .1987; 256: 102–111. 
[15] http://tpe-medecine-technologie.e-
monsite.com/medias/images/image-9.jpg 
[16]  Banerjee R. Liposomes: Applications in Medicine. J 
Biomater Appl. 2001; 16: 3–21 
Kamra et. al
 
 Liposomes in dermatological diseases 
 
 
Journal of Applied Pharmaceutical Research  April  – June 2017  Volume 5 Issue 2  7 
[17]  Barry BW. Penetration enhancers. In: ShrootB, SchäfferH, 
eds. Skin Pharmacokinetics. Karger, Basel, 1987: 121–127 
[18] Dreher F, Walde P, Luist PL, Elsner P. Human skin 
irritation studies of a lecithin microemulsion gel and of 
lecithin liposomes. Skin Pharmacol. 1996; 9: 124–129.  
[19]  Patel H. Liposomes as a controlled-release system. 
BiochemSoc Trans .1985; 13: 513–516.  
[20]  Date AA, Naik B, Nagarsenker MS. Novel drug delivery 
systems: potential in improving topical delivery of 
antiacne agents. Skin PharmacolPhysiol.2006; 19: 2–16.  
[21] Brisaert M, Gabriëls M, Matthijs V, Plaizier–Vercammen 
J. Liposomes with tretinoin: a physical and chemical 
evaluation. J Pharm Biomed Anal. 2001; 26: 909–917.  
[22] Mezei M, Gulasekharam V. Liposomes – a selective drug 
delivery system for the topical route of administration: 
lotion dosage form. Life Sci.1980; 26: 1473–1477.  
[23] http://www.acnenomorereviewer.org/wp-
content/uploads/2012/02/acne-vulgaris.jpg 
[24] Honzak L, Sentjurc M. Development of liposome 
encapsulated clindamycin for treatment of acne vulgaris. 
Eur J Physiol.2000; 440 (Suppl.): 44–45.  
[25] Schäfer-Korting M, Korting HC, Ponce-Pöschl E. 
Liposomal tretinoin for uncomplicated acne vulgaris. Clin 
Invest .1994; 72: 1086–1091.  
[26]  Patel VB, Misra AN, Marfatia YS. Topical liposomal gel 
of tretinoin for the treatment of acne: research and clinical 
implications. Pharm Dev Technol. 2000; 5: 455–464.  
[27]  Patel VB, Misra AN, Marfatia YS. Preparation and 
comparative clinical evaluation of liposomal gel of 
benzoylperoxide for acne. Drug DevInd Pharm .2001; 27: 
863–870.  
[28] Fluhr JW, Barsom O, Gehring W, Gloor M. Antibacterial 
efficacy of benzoylperoxide in phopholipid liposomes. A 
vehicle-controlled, comparative study in patients with 
papulopustular acne. Dermatology. 1999; 198: 273–277.  
[29] https://www.salinetherapy.com/wp-
content/uploads/2013/06/atopic_dermatitis.jpg 
[30] Irvine AD, McLean WHI. Breaking the (un) sound barrier: 
Filaggrin is a major gene for atopic dermatitis. J Invest 
Dermatol.2006; 126: 1200–1202. 
[31]  Palmer CNA, Irvine AD, Terron-Kwiatkowski A, Zhao Y. 
Common loss-of-function variants of the epidermal barrier 
protein filaggrin are major predisposing factor for atopic 
dermatitis. Nat Genet. 2006; 38: 441–446.  
[32]  Lee JH, Lee SJ, Kim DS, Bang D. The effect of wet-wrap 
dressing on epidermal barrier in patients with atopic 
dermatitis. J EurAcadDermatolVenereol. 2007; 21: 1360–
1368.  
[33] Lautenschlager H. Liposomes in dermatological 
preparations. Cosmet Toiletries. 1990; 105: 89–96. 
[34] Sveinsson SJ, Olafsson JH, Valgardsson VS. The effect of 
liposomal moisturizing cream on dry skin: a preliminary 
double-blind study. J Dermatol Treatment .1993; 4: 187–
189.  
[35] Korting HC, Zienicke H, Schafer-Korting M, Braun-Falco 
O. Liposome encapsulation improves efficacy of 
betamethasone dipropionate in atopic eczema but not in 
psoriasis vulgaris. Eur J ClinPharmacol. 1990; 39: 349–
351.  
[36] http://www.pcds.org.uk/ee/images/made/ee/images/upload
s/clinical/gutt_psor_3_800_526_http:www.pcds.org.ukeea
ssetsimgwatermark.gif_0_0_80_r_b_-5_-5_.jpg 
[37] Lebwohl M. Psoriasis. Lancet .2003; 361: 1197–1204.  
[38]  Krueger G, Ellis CN. Psoriasis-recent advances in 
understanding its pathogenesis and treatment. J Am 
AcadDermatol. 2005; 53: s94–s100.  
[39] Körbel JN, Sebök B, Kerényl M, Mahrle G. Enhancement 
of the antiparakeratotic potency of calitriol and tacalcitol 
in liposomal preparations in the mouse tail test. Skin 
PharmacolAppl Skin Physiol. 2001; 14: 291–295.  
[40] Agarwal R, Katare OP, Vyas SP. Preparation and in vitro 
evaluation of liposomal/niosomal delivery systems for 
antipsoriatic drug dithranol. Int J Pharmac. 2001; 228: 43–
52.  
[41] Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A 
randomized, double-blind, vehicle-controlled study of a 
novel liposomal dithranol formulation in psoriasis. J 
Dermatol Treat. 2007; 18: 40–45.  
[42] Verma DD, Fahr A. Synergistic penetration enhancement 
effect of ethanol and phospholipids on the topical delivery 
of cyclosporin A. J Control Release. 2004; 97: 55–66.  
[43] Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable 
liposomes for dermal administration of methotrexate. Int J 
Pharmaceutics. 2004; 270: 119–125.  
[44] Cui J, Shen L, Wang G. Role of hair follicles in the 
repigmentation of vitiligo. J Invest Dermatol .1991; 97: 
410–416. 
Kamra et. al
 
 Liposomes in dermatological diseases 
 
 
Journal of Applied Pharmaceutical Research  April  – June 2017  Volume 5 Issue 2  8 
[45] Ortel B, Tanew A, Honingsman H. treatment of vitiligo 
with khellin and ultraviolet A. J Am AcadDermatol. 1988; 
18: 693–701.  
[46] Orechia G, Sangalli ME, Gazzaniga A, Giordano F. 
Topical photochemotherapy of vitiligo with a new khellin 
formulation: preliminary results. J DermatolTreatm.1998; 
9: 65–69.  
[47]  De Leeuw J, Van Der Beek N, Maierhofer G, Neugebauer 
WD. A case study to evaluate the treatment of vitiligo with 
khellin encapsulated in 1-phenylalanin stabilized 
phophatidylcholine liposomes in combination with 
ultraviolet light therapy. Eur J Dermat.2003; 13: 474–477.  
[48]  Kraemer K. Sunlight and skin cancer. ProcNatlAcadSci 
USA .1997; 94: 11–14.  
[49]  Dahl E, Aberg M, Rausing A, Rausing EL. Basal cell 
carcinoma. Cancer. 1992; 70: 104–108.  
[50]  De Vries E, Van De Poll-Franse LV, Louwman WJ, De 
Gruijl FR, Coebergh JWW. Predictions of skin cancer 
incidence in the Netherlands up to 2015. B J Dermatol. 
2005; 152: 481–488.  
[51] Ananthaswamy HN, Pierceall WE. Molecular mechanism 
of ultraviolet radiation carcinogenesis. 
PhotochemPhotobiol.1990; 52: 19–136.  
[52]  Tanaka K, Sekiguchi M, Okada Y. Restoration of 
ultraviolet-induced unscheduled DNA synthesis of 
xeroderma pigmentation cells by the concomitant 
treatment with bacteriophage T4 endonuclease V and HVJ 
(Sendai virus) ProcNatlAcadSci USA. 1975; 72: 4071–
4075.  
[53] Yarosh D. Liposome-encapsulated enzymes for DNA 
repair. In: Braun-FalcoO, KortingH, MaibachH, eds. 
Liposome Dermatics. Springer-Verlag, Berlin, 1992: 258–
268. .  
[54]  Pierre MBR, Tedesco AC, Marchetti JM, Bentley MVLB. 
Stratum corneum lipids liposomes for the topical delivery 
of 5-aminolevulinic acid in photodynamic therapy of skin 
cancer: preparation and in vitro permeation study. BMC 
Dermatol. 2001; 1: 1–5.  
[55] Panjehpour M, Julius CE, Phan MN, Vo-Dihn T, Overholt 
S. Laser-induced fluorescence spectroscopy for in vivo 
diagnosis of non-melanoma skin cancers. Lasers Surg 
Med..2002; 31: 367–373.  
[56] http://healthsurgical.com/wp-
content/uploads/2016/01/thrombophlebitis-picture.jpg 
[57] Aghassi D, Anderson RR, Gonzalez S. Confocal laser 
microscopic imaging of actinic keratosis in vivo: a 
preliminary report. J Am AcadDermatol. 2000; 43: 42–48.  
[58]  Smits T, Kleinpenning MM, Blokx WAM, Van Der 
Kerkhof PCM, Van Erp PEJ, Gerritsen MJP. Fluorescence 
diagnosis in keratinocyticintraepidermalneoplasias. J Am 
AcadDermatol.2007; 57: 824–831.  
[59] Kleinpenning MM, Smits T, Ewalds E, Van Erp PEJ, Van 
De Kerkhof PCM, Gerritsen MJP. Heterogeneity of 
fluorescence in psoriasis after application of 5-
aminolaevulinic acid: an immunohistochemical study. Br J 
Dermatol. 2006; 155: 539–545. 
[60]  Sand M, Bechara FG, Sand D, Altmeyer P, Hoffmann K. 
A randomized, controlled, double-blind study evaluating 
melanin-encapsulated liposomes as a chromophore for 
laser hair removal of blond, white, and grey hair. Ann Plast 
Surg. 2007; 58: 551–554.  
[61]  Tierney E, Goldberg DJ. Laser hair removal pearls. J 
Cosm Laser Ther.2008; 10: 17–23.  
[62] Taddio A, KaurSoin H, Schuh S, Koren G, Scolni D. 
Liposomal lidocaine to improve procedural success rates 
and reduce procedural pain among children: a randomized 
controlled trial. CMAJ. 2005; 172: 1691–1695.  
[63]  Gold MH. Photodynamic therapy with lasers and intense 
pulsed light. Facial PlastSurgClin N Am .2007; 15: 145–
160.  
[64]  Biter PH. Noninvasive rejuvenation of photodamaged skin 
using serial, full-face intense pulsed light treatments. 
DermatolSurg.2000; 26: 835–842.  
[65] Touma D, Yaar M, Whitehead S. A trial of short 
incubation, broad-area photodynamic therapy for facial 
actinic keratoses and diffuse photodamage. Arch 
Dermatol.2004; 140: 33–40.  
[66]  Olsen EA, Katz HI, Levine N. Tretinoin emollient cream: 
a new therapy for photodamaged skin. J Am 
AcadDermatol. 1992; 26: 215–224.  
[67] Lippman SM, Meyskens FL. Results of the use of vitamin 
A and retinoids in cutaneous malignancies. 
PharmacTher.1989; 40: 107–122.  
[68] Sinico C, Manconi M, Peppi M, Lai F, Valenti D, Fadda 
AM. Liposomes as carriers for dermal delivery of 
tretinoin: in vitro evaluation of drug permeation and 
vesicle–skin interaction. J Controlled Rel.2005; 103: 123–
136.  
